SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Addiction Medicine Consultation — Billie Holiday
| Patient | Billie Holiday |
|---|
| Date of birth | 1993-04-07 |
|---|
| Identifiers | MRN HR-ML010-SYN; SSN (made up) 000-10-4472 |
|---|
| Document date | 2026-04-27 |
|---|
| Author | Julian Ortiz, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Severe opioid use disorder and moderate alcohol use disorder in a 33-year-old singer, five weeks after release from about ten months in custody, when her tolerance is low and her overdose risk high. Buprenorphine with naloxone was started today. Please confirm the medication plan and dose, advise on a medicine for her drinking that is safe with buprenorphine, and help set the monitoring and recovery plan. [S]
Urgency: Within one week, on the same day as her one-week primary care visit. [S]
Questions for the consultant:
- Is buprenorphine the right medication for her, and what dose should we aim for?
- Which medicine for alcohol use disorder can she take with buprenorphine?
- How should we read her liver tests, and does she need more than FIB-4 to stage fibrosis?
- What monitoring do you advise, including urine drug testing and visit frequency?
- How should we respond if she returns to opioid use?
History of Present Illness
Ms. Holiday, a 33-year-old singer, is seen at the request of Dr. Mayfield one week after starting buprenorphine with naloxone. She has taken every dose, 4 mg on the first day and 8 mg since, and has used no opioids. She has had no withdrawal, but cravings return each evening, especially after shows. She drinks four or five drinks on performance nights to calm her nerves. She has no history of withdrawal seizures or delirium. She sought treatment for heroin use years ago and says she wants to stay off it and keep singing. Her biggest fear is overdosing now that her tolerance is low. She tours often and worries about getting prescriptions filled on the road. She asked that this note be shared only with Dr. Mayfield. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Billie Holiday was born Eleanora Fagan in Philadelphia on April 7, 1915, and was raised in Baltimore by her mother, Sarah Julia "Sadie" Fagan. [D]
- Her mother died in October 1945; afterwards Holiday drank more heavily and her drug use increased as she grieved. [D]
- Holiday began using heroin in the early 1940s, and her addiction became severe in the late 1940s; she was arrested repeatedly over her heroin use in that period. [D]
- In May 1947 Holiday was arrested for narcotics possession; she pleaded guilty, was sentenced to a year and a day, and was held at the federal facility for women at Alderson, West Virginia, until her early release on March 16, 1948. [D]
- Holiday sought treatment for her addiction, at one point checking herself into an institution in the hope of breaking her habit. [D]
- Her conviction cost her the New York City cabaret card she needed to perform in clubs that served alcohol. [D]
- The Federal Bureau of Narcotics pursued Holiday for years, and later writers have described that pursuit as driven by racism and linked it to her performance of "Strange Fruit," a song against lynching. [R]
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily | One film under the tongue daily after a 4 mg first dose | Sublingual route | 2026-04-20 to 2026-04-27 | completed | S |
| Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily | Two films under the tongue once daily | Sublingual route | 2026-04-27 | active | S |
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response | Nasal route | 2026-04-20 | active | S |
| Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily | Two tablets by mouth three times daily | Oral route | 2026-04-27 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-04-20 to 2026-10-19 | completed | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin use | active | confirmed |
F11.20 | S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use. |
| Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's death | active | confirmed |
F10.20 | S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode. |
Physical Exam
Vital signs recorded on 2026-04-27; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Alert and engaged; blood pressure 122/78, pulse 78 |
| Eyes | Pupils normal in size; no tearing |
| Skin | No injection-site changes or abscesses |
| Neurological | No tremor |
| Psychiatric | Calm and direct; no signs of intoxication or withdrawal |
Assessment
- Opioid use disorder, severe, early in buprenorphine treatment (F11.20). Buprenorphine is a good choice: it lowers the risk of overdose death, can be prescribed from primary care, and fits her touring better than daily methadone clinic attendance, which remains an option if buprenorphine does not control her cravings. Extended-release naltrexone would need a long opioid-free period and does not protect her if she loses tolerance and uses again. Starting at a low dose was right after enforced abstinence. Evening cravings at 8 mg mean the dose is too low; most people do best at 16 mg or more. [S]
- Alcohol use disorder, moderate (F10.20). Naltrexone, the usual first choice, cannot be used with buprenorphine. Acamprosate is safe with buprenorphine and with her normal kidney function; topiramate is a second choice. Her withdrawal risk is low, so she does not need a medically managed withdrawal. [S]
- Liver. AST higher than ALT with a raised GGT and a high MCV points to alcohol. Albumin, bilirubin, and platelets are normal, and FIB-4 is 1.18, below 1.3, so advanced fibrosis is unlikely and elastography is not needed now. Repeating liver tests as drinking changes, and FIB-4 within a year, is enough. She is not immune to hepatitis B and should complete the series. [S]
- Return to use. A return to use is common and is a reason to strengthen treatment, not to stop it. Her greatest risk is a gap in her medication while touring. [S]
Data reviewed: Dr. Mayfield's intake note with the safety assessment, AUDIT-C, DAST-10, and PHQ-9. Last week's results: AST 52, ALT 38, GGT 84 U/L; albumin 4.0 g/dL; bilirubin 0.7 mg/dL; MCV 101 fL; platelets 236; creatinine 0.72 mg/dL; PEth 312 ng/mL; hepatitis C antibody nonreactive (0.09); hepatitis B surface antigen and core antibody nonreactive, surface antibody 3 mIU/mL; HIV antigen-antibody nonreactive. Today's urine drug test: buprenorphine and norbuprenorphine only. Prescription drug monitoring program: no other controlled-substance prescriptions. [S]
Plan of Treatment
- Increase buprenorphine with naloxone to 16 mg once daily today. [S]
- Start acamprosate 666 mg three times daily; continue thiamine while she drinks heavily. [S]
- Naloxone at home and in her bag, with her friend trained; fentanyl test strips; never use alone. [S]
- Visits every one to two weeks for the first month, then every two to four weeks until stable, then monthly; telehealth check-ins when she is on tour. [S]
- Urine drug testing with fentanyl at most visits early on, explained as part of care, never as a condition of treatment; check the prescription drug monitoring program before each prescription. [S]
- PEth with liver tests at each check while she is drinking; FIB-4 again at six to twelve months; elastography only if FIB-4 reaches 1.3. [S]
- Complete the hepatitis A and B vaccine series; repeat hepatitis C and HIV testing yearly while any drug use continues. [S]
- If she returns to use, keep her on buprenorphine, increase support, and look for the cause; consider monthly extended-release buprenorphine if gaps in supply recur. [S]
- Plan for tours before each trip: a pharmacy chain that can fill in any state, prior authorization kept current, an early fill, and a travel letter. [S]
- Offer counseling and peer recovery support without making them a condition of medication. [S]
- Discussed with Dr. Mayfield, who sees her the same day. The plan was explained to Ms. Holiday, who agreed with it; at her request this note is shared only with Dr. Mayfield and is held under the federal confidentiality rule for substance use disorder records. [S]
- Follow-up: Addiction medicine review at three months or sooner if there is a return to use; Dr. Mayfield continues prescribing. [S]